ZYME

#1712
Zymeworks Inc. - Common Stock
25.1 3 USD
-1.37%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
25.13
25.13
Range Annuel
16.00
29.75
Changement quotidien
-1.37%
Changement Mensuel
-10.17%
Evolution sur 6 mois
-5.03%
Changement Annuel
+41.66%
Clôture Précédente
25.4 8
Open
25.1 3
Low
25.1 3
High
25.1 3
Volume
112
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 1.84 B
  • Employee 264
  • Founded 2003
  • CEO Kenneth Galbraith
  • Website www.zymeworks.com
  • Headquarter Delaware, United States
  • FIGI BBG019XSYC89
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-24.38
ratio cours/chiffre d'affaires
18.74

Zymeworks Inc. - Common Stock

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

Nouvelles